Hypercalciuria is a common cause for stone formation in children. The aim was to delineate the role of urinary citrate in hypercalciuric children for protection against calcium stone formation. We evaluated random urine calcium, citrate, and creatinine in 149 controls, 78 hypercalciuric nonstone formers, and 34 hypercalciuric children with stone. Urine citrate/creatinine was highest in hypercalciuric nonstone formers 899 Ϯ 351 compared with controls 711 Ϯ 328 and stone formers 595 Ϯ 289 (p Ͻ 0.01 vs. both). Calcium/creatinine ratio was similar in hypercalciuric stone and nonstone formers, but significantly higher than controls. Consequently, urine Calcium/citrate ratio (mg/mg) increased from control 0.17 Ϯ 0.17 to 0.41 Ϯ 0.23 (p Ͻ 0.001) in hypercalciuric nonstone formers, and to 0.65 Ϯ 0.46 in stone formers (p Ͻ 0.001 compared with other groups). Area under receiver operating characteristic curve combined with multilevel risk analyses found calcium/citrate ratio of 0.326 to provide good discrimination between control and stone formers. We found 5th percentile for random urine citrate/creatinine ratio in school-aged children to be 176 mg/g, elevated urinary citrate excretion in hypercalciuric children to be protective against stone formation, and urine calcium/citrate ratio to be a good indicator for risk of stone formation. Whether intervention in hypercalciuric children to lower urine calcium/citrate Ͻ0.326 will provide protection against stone formation needs to be studied. (Pediatr Res 66: 85-90, 2009) T he incidence of urolithiasis in children has increased in recent years (1). The risk factors for urolithiasis commonly observed in children are low urine volume, increased urine calcium excretion, and low normal or decreased urinary citrate level (2). Citrate inhibits the spontaneous nucleation of calcium oxalate, crystal growth of calcium oxalate and calcium phosphate, and the heterogeneous nucleation of calcium oxalate by monosodium urate (3-8). Bisaz et al. (9) reported that citrate is responsible for 50% of the inhibitory activity against calcium phosphate precipitation in normal urine. The inhibitory effect of citrate on calcium oxalate crystal growth and aggregation is also linked to a direct effect on the crystal surface (3,10). Consequently, and because of lack of significant adverse effects, citrate preparations are widely used in subjects with calcium oxalate nephrolithiasis (2,11-13).In adult studies, Welshman and McGeown (14), Hobarth and Hofbauer (15) and Nikkila et al. (16) observed that urine calcium/citrate ratio was able to discriminate between stone formers and control population; the latter exhibiting a significantly lower calcium/citrate ratio. However, it was the impression in the above studies that the clinical use of urine calcium/citrate ratio was limited because of its wide range of variability and the influence of age and gender on urinary excretion of citrate. There is limited data on urine calcium/ citrate ratio in either healthy, hypercalciuric, or stone forming child...